Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II of Sunitinib (SUTENT®) in First Line for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma - SUPAP

NCT00541008 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT00541008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00541008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II of Sunitinib (SUTENT®) in First Line for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma - SUPAP
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
September 5, 2007
Completion date
April 30, 2013
Enrollment
92 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer